Partner with Ultragenyx to solve their R&D challenges
15-06-2023
X
Watch webinar
Enter your details below to access the audio and video recording of this event, and to receive updates about future virtual events.
If you’re already subscribed to IN-PART, please enter your details and you’ll be taken to the recordings.
By registering to attend you agree to receive emails about our virtual events. You can unsubscribe at any time through these emails. Information about how we store and process data in compliance with GDPR is outlined in our privacy policy.
In the second event of our latest Virtual Series, we spoke with Chris Hamblett, Vice President, Business Development, and Mika Aoyagi-Scharber, Executive Director, Translational Research, Program & Portfolio Management at Ultragenyx. In this partnering event with Ultragenyx, we heard about their rare disease R&D priorities and the research they’re seeking from academia.
Format: Presentation followed by live Q&A (~40 minutes)
- 00:00 – Intro to IN-PART
- 03:48 – Intro to Ultragenyx
- 09:12 – Ultragenyx’s pipeline and commercial portfolio
- 14:06 – Ultragenyx’s partnering approach
- 20:18 – R&D challenges and priority area
- 28:25 – Live Q&A 37:36 – Final comments
As part of our current Global Challenge seeking novel rare disease research and assets, Ultragenyx have shared their interests through this webinar and in a one-page summary (company interests and priorities), with the view to identify new academic partners for collaboration and commercialisation partnerships.
About the company: Ultragenyx is a biopharmaceutical company focused on developing transformative products for the treatment of rare and ultrarare diseases. The company has a diverse portfolio of approved therapies across multiple therapeutic modalities aimed at addressing diseases with clear biology and high unmet medical need, for which there are typically no approved therapies.
Run in partnership with:
ASTP are Europe’s premier association of knowledge transfer professionals whose work aims to improve the quality of impact that public research has on the economy and society. Learn more.
PraxisAuril are a world-leading professional association for
knowledge exchange practitioners, whose network includes 5000+ KE professionals. Learn more.
Labiotech.eu provide the biotech community with current and relevant information about the life sciences industry. They hope that professionals in the industry will collaborate more effectively so they can develop better products that benefit our society. Learn more.
BIA: The BioIndustry Association (BIA) is the voice of the innovative life sciences and biotech industry, enabling and connecting the UK ecosystem so that businesses can start, grow and deliver world-changing innovation. Learn more.
Healx is a global AI-powered techbio company redesigning drug discovery to develop treatments for rare diseases at scale. Learn more.
Copyrights reserved unless otherwise agreed – IN-PART Publishing Ltd., 2023: ‘Virtual partnering event with Ultragenyx’
What is IN-PART?
IN-PART develops digital solutions, curated by in-house STEM experts, that simplify the initial connection between decision-makers in academia and industry. Our goal is to help drive impact from research by matching innovation and expertise on a level playing field globally.
Connect, a digital partnering platform for university-industry collaboration.
An online matchmaking platform used by 250+ universities and research institutes to connect with industry teams in 6,000+ companies to commercialise academic innovations and expertise that are available and seeking collaboration.
Discover, a bespoke scouting service for open innovation.
A bespoke scouting platform used by innovation-driven companies to profile the global landscape of academia across an active network of 2,600+ institutes, either through ‘Industry Calls for Opportunities’ or ‘Request for Proposal’ campaigns that find and confirm potential solutions to specific R&D challenges or requirements.